ObjectiveTo observe the changes of peripheral blood lymphocyte subsets of patients with primary hepatocellular carcinoma (PHCC) treated with radiofrequency ablation (RFA). MethodsThe data of 70 cases of hospitalized patients with PHCC that voluntary accepted RFA diagnosed by clinical and pathological in our hospital between July 2011 and December 2014 were collected. According to the numbers of HCC lesions, 70 cases were divided into single focus group (n=41) and multifocal group (n=29). The changes of their immune parameters before and after RFA were analyzed. Results①The ratioes of peripheral blood CD3+/CD19-, CD3+/CD4+, CD4+/CD8+, and NK cells on 7 days and 14 days after RFA treatment of 70 cases were significantly higher than those on 1 day before RFA treatment (P < 0.05). The ratio of CD3+/CD8+ T cells reduced from 1 day before RFA treatment to 14 days after RFA treatment, but the difference was no statistically significant (P > 0.05).②The changing trend of peripheral blood lymphocyte subsets before and after RFA treatment in single focus group and multifocal group were similar to the above.③Compared with single focus group, the ratioes of peripheral blood CD3+/CD19-, CD3+/CD4+, CD4+/CD8+, and NK cells before and after RFA treatment in multifocal group were lower, and the ratio of CD3+/CD8+ T cells was higher, but the difference were not statistically significant (P > 0.05). ConclusionRFA can not only destroy small PHCC foci, but also to significantly improve immune function and enhance the anti-tumor effect.
目的 探讨射频消融术在无法实施手术的原发性肝癌患者中的临床应用效果。方法 回顾性分析2007年9月至2011年3月期间我院收治的58例由于各种原因无法手术治疗的大肝癌（＞5cm）并接受射频消融治疗患者的临床资料，射频消融前后结合超声造影的方法，术后随访并定期复查血清甲胎蛋白水平和超声造影或者肝脏增强CT。结果 58例中无一例发生与射频消融相关的死亡，22例达到完全消融（37.9%，22/58）。共51例（87.9%，51/58）获得随访，随访至2012年5月，随访时间（12.6±6.4）个月（2～21个月），随访12个月以上患者有20例（39.2%，20/51），有10例（19.6%，10/51）无肿瘤复发或者转移的迹象。22例达到完全消融的患者无瘤生存时间为（13.6±10.4）个月（3～21个月）；36例未能达到完全消融的患者中，有19例随访期间死亡，生存时间（8.3±6.1）个月（4～16个月）。结论 由于各种原因不能接受手术的大肝癌患者，射频消融作为一种有效、安全治疗方法，部分能达到完全消融的效果，而部分作为姑息性治疗手段，能一定程度上减轻患者的疼痛，达到提高生活质量的目的。